So RAMPART is an investigator-led phase 3 trial in participants with resected renal cell carcinoma at intermediate or high risk of recurrence and in some selected patients with resected metastatic disease. And participants were randomised in a 3 to 2 to 2 ratio to either active monitoring, atezolizumab monotherapy for one year, or durvalumab for a year with tremelimumab at day one and week four...
So RAMPART is an investigator-led phase 3 trial in participants with resected renal cell carcinoma at intermediate or high risk of recurrence and in some selected patients with resected metastatic disease. And participants were randomised in a 3 to 2 to 2 ratio to either active monitoring, atezolizumab monotherapy for one year, or durvalumab for a year with tremelimumab at day one and week four. So Rampart’s previously reported its efficacy results, which showed that durvalumab and tremelimumab demonstrated a disease-free survival benefit, whereas atezolizumab monotherapy did not. When we look at the safety between the three, there were higher rates of grade four adverse events with the combination of atezolizumab and tremelimumab and then with durvalumab compared to active monitoring. But interestingly, when we looked at our primary quality of life outcome, they showed no evidence of a difference between arms. So today we are presenting patient reported outcomes, more detailed patient reported outcomes beyond that primary quality of life endpoint. And what we’ve shown is despite no difference in that primary outcome, a number of functional domains and symptom and item subscales were worse with durvalumab monotherapy than with active monitoring, so that that primary quality of life endpoint wasn’t fully capturing the patient experience.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.